Vertex announces us fda approval of casgevy™ (exagamglogene autotemcel) for the treatment of transfusion-dependent beta thalassemia

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) announced today that the u.s. food and drug administration (fda) has approved casgevy™ (exagamglogene autotemcel [exa-cel]), a crispr/cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (tdt) in patients 12 years and older. “on the heels of the historic fda approval of casgevy for sickle cell disease, it is exciting to now secure approval for tdt well ahead of the pdufa date,” said.
VRTX Ratings Summary
VRTX Quant Ranking